Bristol-Myers Squibb’s $74 billion acquisition of Celgene needs surgery. rob_cyran
Wellington Management has told the board of Bristol-Myers Squibb that it does not support the company’s $74 billion acquisition of Celgene, it said on Feb. 27. The fund manager owns about 8 percent of the drugmakers’ shares.
Wellington said the deal was too risky and offered Bristol-Myers shares at a price well below implied asset value, that management was underestimating the difficulty of successful execution, and that there were “alternative paths to create value” which could be more attractive to Bristol-Myers. Dodge & Cox, the company’s fifth-largest shareholder, is also unhappy with the deal, according to sources cited by Reuters.
Starboard Value, an activist fund, also said it was against the deal on Feb. 28 and that, should the acquisition be voted down, it would nominate a slate of directors to Bristol-Myers’ board.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Baca lebih lajut »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Baca lebih lajut »
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Baca lebih lajut »
Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Baca lebih lajut »
Starboard Details Opposition to Bristol-Myers Deal for CelgeneActivist investor Starboard Value detailed its opposition to Bristol-Myers Squibb’s proposed acquisition of Celgene, describing the proposed takeover as poorly conceived and ill advised.
Baca lebih lajut »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Baca lebih lajut »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Baca lebih lajut »
Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Baca lebih lajut »